Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Rivers

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Infectious Diseases|November 12, 2024
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential WorkersJosephine Mak, Sana Khan, Amadea Britton, et al.
Diseases (Basel, Switzerland)|August 28, 2024
Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal CohortCynthia Porter, Zoe L Lyski, Jennifer L Uhrlaub, et al.
MMWR. Morbidity and Mortality Weekly Report|September 1, 2022
Parental Intentions and Perceptions Toward COVID-19 Vaccination Among Children Aged 4 Months to 4 Years - PROTECT Cohort, Four States, July 2021-May 2022Karen Lutrick, Ashley Fowlkes, Patrick Rivers, et al.
Emerging Infectious Diseases|January 26, 2023
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline WorkersKatherine D Ellingson, James Hollister, Cynthia J Porter, et al.
MMWR. Morbidity and Mortality Weekly Report|April 1, 2021
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021Mark G Thompson, Jefferey L Burgess, Allison L Naleway, et al.
JAMA|October 18, 2022
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers, Mark G Thompson, Sarang K Yoon, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022Ashley L Fowlkes, Sarang K Yoon, Karen Lutrick, et al.
JMIR Research Protocols|May 31, 2022
Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort StudyJoy Burns, Patrick Rivers, Lindsay B LeClair, et al.
The New England Journal of Medicine|June 30, 2021
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesMark G Thompson, Jefferey L Burgess, Allison L Naleway, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Infectious Diseases|November 12, 2024
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential WorkersJosephine Mak, Sana Khan, Amadea Britton, et al.
Diseases (Basel, Switzerland)|August 28, 2024
Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal CohortCynthia Porter, Zoe L Lyski, Jennifer L Uhrlaub, et al.
MMWR. Morbidity and Mortality Weekly Report|September 1, 2022
Parental Intentions and Perceptions Toward COVID-19 Vaccination Among Children Aged 4 Months to 4 Years - PROTECT Cohort, Four States, July 2021-May 2022Karen Lutrick, Ashley Fowlkes, Patrick Rivers, et al.
Emerging Infectious Diseases|January 26, 2023
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline WorkersKatherine D Ellingson, James Hollister, Cynthia J Porter, et al.
MMWR. Morbidity and Mortality Weekly Report|April 1, 2021
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021Mark G Thompson, Jefferey L Burgess, Allison L Naleway, et al.
JAMA|October 18, 2022
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers, Mark G Thompson, Sarang K Yoon, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022Ashley L Fowlkes, Sarang K Yoon, Karen Lutrick, et al.
JMIR Research Protocols|May 31, 2022
Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort StudyJoy Burns, Patrick Rivers, Lindsay B LeClair, et al.
The New England Journal of Medicine|June 30, 2021
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesMark G Thompson, Jefferey L Burgess, Allison L Naleway, et al.
Pageof 3